Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2014 Apr;5(2):E46-9.
doi: 10.3978/j.issn.2078-6891.2014.012.

Spontaneous tumor lysis syndrome in a patient with cholangiocarcinoma

Alaa M Ali  1 , Aram Barbaryan  1 , Teresita Zdunek  1 , Maliha Khan  1 , Prakruthi Voore  1 , Aibek E Mirrakhimov  1
Affiliations
Case Reports

Spontaneous tumor lysis syndrome in a patient with cholangiocarcinoma

Alaa M Ali et al. J Gastrointest Oncol. 2014 Apr.

Abstract

Tumor lysis syndrome (TLS) is a potentially deadly complication of tumors or their treatment. This syndrome consists of a constellation of laboratory parameters such as hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia and clinical complications such as seizures, acute renal insult, cardiac dysrhythmias and death. TLS is especially common in patients with hematological malignancies with rapid cellular turnover rates such as acute lymphocytic leukemia and Burkitt lymphoma, but is very rare in patients with solid tumors. However, it is essential to keep in mind that solid tumors can also lead to TLS. We present a case of a 66-year-old African American male with metastatic cholangiocarcinoma complicated by the development of spontaneous TLS. TLS has never been reported in a patient with cholangiocarcinoma.

Keywords: Cholangiocarcinoma; acute renal failure; tumor lysis syndrome (TLS).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Multiple tiny ill-defined lesions scattered throughout the liver and ascites.
Figure 2
Figure 2
Strongly positive immunostain for cytokeratin 19 (IHC 20×).
See this image and copyright information in PMC

References

    1. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004;127:3-11 - PubMed
    1. Wilson FP, Berns JS. Onco-nephrology: tumor lysis syndrome. Clin J Am Soc Nephrol 2012;7:1730-9 - PubMed
    1. Will A, Tholouli E.The clinical management of tumour lysis syndrome in haematological malignancies. Br J Haematol 2011;154:3-13 - PubMed
    1. Mika D, Ahmad S, Guruvayoorappan C.Tumour lysis syndrome: implications for cancer therapy. Asian Pac J Cancer Prev 2012;13:3555-60 - PubMed
    1. McBride A, Westervelt P.Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies. J Hematol Oncol 2012;5:75. - PMC - PubMed

Publication types